Rekah Pharmaceutical Industry Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was ILS 76.66 million compared to ILS 66.85 million a year ago. Net loss was ILS 1.1 million compared to ILS 0.517 million a year ago. Basic loss per share from continuing operations was ILS 0.1 compared to ILS 0.05 a year ago.
For the six months, sales was ILS 155.66 million compared to ILS 139.31 million a year ago. Net loss was ILS 0.518 million compared to net income of ILS 0.022 million a year ago. Basic loss per share from continuing operations was ILS 0.05.